(105) Kravec M, Šedo O, Nedvědová J, Micka M, Šulcová M, Zezula N, Gömöryová K, Potěšil D, Ganji SR, Bologna S, Červenka I, Zdráhal Z, Harnoš J, Tripsianes K, Janke C, Barinka C, Bryja V*: Novel polyglutamylation mechanism regulates signaling and phase separation of protein Dishevelled. EMBO J, 2024, in press. 
(104) Nickl P, Jenickova I, Elias J, Kasparek P, Barinka C, Kopkanova J, Sedlacek R*: Multistep allelic conversion in mouse pre-implantation embryos by AAV vectors. Sci Rep, 2024, 14(1):20160.
(103) Scheuerer S, Motlova L, Schäker-Hübner L, Sellmer A, Feller F, Ertl FJ, Koch P, Hansen FK, Barinka C, Mahboobi S*: Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability. Eur J Med Chem, 2024, 276:116676.
(102) Baselious F, Hilscher S, Hagemann S, Tripathee S, Robaa D, Barinka C, Huttelmaier S, Schutkowski M, Sippl W*: Utilization of an Optimized AlphaFold Protein Model for Structure-Based Design of a Selective HDAC11 Inhibitor with Anti-neuroblastoma Activity. Arch Pharm, 2024, e2400486.
(101) Panigrahi A*, Benicky J, Aljuhani R, Mukherjee P, Nováková Z, Bařinka C, Goldman R*: Galectin-3-binding protein inhibits extracellular heparan 6-O-endosulfatase Sulf-2. Mol Cell Proteomics, 2024, 23(7), 100793.
(100) Liatsou I, Assefa B, Liyanage W, Surasinghe S, Nováková Z, Bařinka C, Gabrielson K, Raman V, Artemov D, Hapuarachchige S*: Development of 5D3-DM1: Development and Therapeutic Evaluation of 5D3(CC-MLN8237)3.2 Antibody-Theranostic Conjugates for PSMA-Positive Prostate Cancer Therapy. Frontiers in Pharmaceut, 2024, 15: 1385598.
(99) Baselious F, Hilscher S, Robaa D, Barinka C, Schutkowski M, Sippl W*: Comparative structure-based virtual screening utilizing optimized AlphaFold model identifies selective HDAC11 inhibitor. Int J Mol Sci, 2024, 25(2):1358.
(98) Novakova Z, Tehrani ZA, Jurok R, Motlova L, Kutil Z, Pavlicek J, Shukla S, Choy CJ, Havlinova B, Baranova P, Berkman CE, Kuchar M, Cerny J, Barinka C*: Structural, biochemical, and computational characterization of sulfamides as bimetallic peptidase inhibitors. J Chem Inf Model, 2024, 64(3):1030-1042.
(97) Panska L*, Nedvedova S, Vacek V, Krivska D, Konecny L, Knop F, Kutil Z, Skultetyova L, Leontovyc A, Ulrychova L, Sakanari J, Asahina M, Barinka C, Macurkova M, Dvorak J: Uncovering the essential roles of glutamate carboxypeptidase 2 orthologs in Caenorhabditis elegans. Biosci Reports, 2024, 44(1):BSR20230502.
(96) Das G, Ptacek J, Havlinova B, Nedvedova J, Barinka C, Novakova Z*: Targeting prostate cancer using bispecific T-cell engagers against prostate-specific membrane antigen. ACS Pharmacol Transl Sci, 2023, 6(11):1703-1714.
(95) Motlova L, Snajdr I, Kutil Z, Andris E, Ptacek J, Novotna A, Novakova Z, Havlinova B, Tueckmantel W, Draberova H, Majer P, Schutkowski M, Kozikowski A, Rulisek L*, Barinka C*: Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6). ACS Chem Biol, 2023, 18(7):1594-1610.
(94) Zessin M, Meleshin M, Hilscher S, Schiene-Fischer C, Barinka C, Jung M, Schutkowski M*: Continuous fluorescent sirtuin activity assay based on fatty acylated lysines. Int J Mol Sci, 2023, 24(8):7416.
(93) Morath V, Brandt C, Deuschle FC, Mendler CT, Blechert B, Summer D, Barinka C, Decristoforo C, Weber WA, Schwaiger M, Skerra A*: Molecular Design of 68Ga- and 89Zr-labeled Anticalin radioligands for PET-imaging of PSMA-positive tumors. Mol Pharmaceut, 2023, 20(5):2490-2501.
(92) Ptacek J, Snajdr I, Schimer J, Kutil Z, Mikesova J, Baranova P, Havlinova B, Tueckmantel W, Majer P, Kozikowski A, Barinka C*: Selectivity of hydroxamate- and difluoromethyloxadiazole-based inhibitors of histone deacetylase 6 in vitro and in cells. Int J Mol Sci, 2023, 24(5):4720.
(91) Temml V, Kollár J, Schönleitner T, Höll A, Schuster D, Kutil Z*: Combination of In Silico and In Vitro Screening to Identify Novel Glutamate Carboxypeptidase II Inhibitors. J Chem Inf Model, 2023, 63(4):1249-1259.
(90) Lake BPM, Ryan RG, Barinka C, Rullo AF*: Tunable Synthetic Multivalent Platform for Immune Recruitment to Lower Antigen Expressing Cancers. Angew Chem Int Ed Engl, 2023, 62(9):e202214659.
(89) Mikesova J, Ondrakova M, Jelinkova I, Ptacek J, Novakova Z, Barinka C*: Determining Potency of Inhibitors Targeting Histone Deacetylase 6 by Quantification of Acetylated Tubulin in Cells. Methods Mol Biol, 2023, 2589:455-466.
(88) Klimesova K, Petrzilkova H, Barinka C, Stanek D*: SART3 associates with a post-splicing complex. J Cell Sci, 2023, 136(2):jcs260380.
(87) Shukla S, Komarek J, Novakova Z, Nedvedova J, Ustinova K, Vankova P, Kadek A, Uetrecht C, Mertens H, Barinka C*: In-solution structure and oligomerization of human histone deacetylase 6 – an integrative approach. FEBS J, 2023, 290(3):821-836.
(86) Jedlickova L, Peterkova K, Boateng EM, Ulrychova L, Vacek V, Kutil Z, Jiang Z, Novakova Z, Snajdr I, Kim J, O’Donoghue AJ, Barinka C, Dvorak J*: Characterization of glutamate carboxypeptidase 2 orthologs in trematodes. Parasit Vectors, 2022, 15(1):480.
(85) Novakova Z*, Milosevic M, Kutil Z, Ondrakova M, Havlinova B, Kasparek P, Sandoval-Acuña C, Korandova Z, Truksa J, Vrbacky M, Rohlena J, Barinka C*: Generation and characterization of human U-2 OS cell lines with the CRISPR/Cas9-edited protoporphyrinogen oxidase IX gene. Sci Rep, 2022, 12(1):17081.
(84) Cihlarova Z, Kubovciak J, Sobol M, Krejcikova K, Sachova J, Kolar M, Stanek D, Barinka C, Yoon G, Caldecott KW, Hanzlikova H*: BRAT1 links Integrator and defective RNA processing with neurodegeneration. Nat Commun, 2022, 13(1):5026.
(83) Zessin M, Meleshin M, Praetorius L, Sippl W, Barinka C, Schutkowski M*: Uncovering robust delactoylase and depyruvoylase activities of HDAC isoforms. ACS Chem Biol, 2022, 17(6):1364-1375.
(82) Kutil Z, Meleshin M, Baranova P, Havlinova B, Schutkowski M*, Barinka C*: Characterization of the class IIa histone deacetylases substrate specificity. FASEB J, 2022, 36(5):e22287.
(81) Novais SM, Blecha J, Naraine R, Mikesova J, Abaffy P, Pecinova A, Milosevic M, Bohuslavova R, Prochazka J, Khan S, Novotna E, Sindelka R, Machan R, Dewerchin M, Vlcak E, Kalucka J, Hubackova S, Benda A, Goveia J, Mracek T, Barinka C, Carmeliet P, Neuzil J*, Rohlenova K*, Rohlena J*: Mitochondrial respiration supports autophagy to provide stress resistance during quiescence. Autophagy, 2022, 18(10):2409-2426.
(80) Ibrahim HS, Abdelsalam M, Zeyn Y, Zessin M, Mustafa AM, Fischer MA, Zeyen P, Sun P, Bülbül EF, Vecchio A, Erdmann F, Schmidt M, Robaa D, Barinka C, Romier C, Schutkowski M, Krämer OH,* Sippl W*: Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors active in leukemic cells. Int J Mol Sci, 2022, 23(1), 369.
(79) Novakova Z, Mikesova J, Ondrakova M, Kutil Z, Vesela K, Martasek P*, Barinka C*: Molecular characterization of a novel His333Arg variant of human protoporphyrinogen oxidase IX. Biochem Biophys Res Commun, 2022, 588:182-186.
(78) Bím D, Navrátil M, Gutten O, Konvalinka J, Kutil Z, Culka M, Navrátil V, Alexandrova AN, Bařinka C*, Rulíšek L*: Predicting Effects of Site-Directed Mutagenesis on Enzyme Kinetics by QM/MM and QM Calculations: A Case of Glutamate Carboxypeptidase II. J Phys Chem B, 2022, 126(1):132-143.
(77) Yuan W, Liu B, Sanda M, Wei R, Benicky J, Novakova Z, Barinka C*, Goldman R: Glycoforms of human Prostate-specific membrane antigen (PSMA) in human cells and prostate tissue. Prostate, 2022, 82(1):132-144.
(76) Novakova Z, Khuntsaria D, Gresova M, Mikesova J, Havlinova B, Shukla S, Kolarova L, Vesela K, Martasek P, Barinka C*: Heterologous expression and purification of recombinant human protoporphyrinogen oxidase IX: a comparative study. PLoS One, 2021, 16(11):e0259837.
(75) Zessin M, Meleshin M, Simic Z, Kalbas D, Arbach M, Gebhardt P, Melesina J, Liebscher S, Bordusa F, Sippl W, Barinka C, Schutkowski M* : Continuous Sirtuin/HDAC (histone deacetylase) activity assay using thioamides as PET (Photoinduced Electron Transfer)-based fluorescence quencher. Bioorg Chem, 2021, 117:105425.
(74) Zhang J#, Rakhimbekova A#, Duan X#, Yin Q, Foss CA, Fan Y, Xu Y, Li X, Cai X, Kutil Z, Wang P, Yang Z, Zhang N, Pomper MG, Wang Y*, Bařinka C*, Yang X*: A PSMA-activated molecular rotor for real-time fluorescence imaging. Nat Commun, 2021, 12(1):5460.
(73) Shen S, Picci C, Ustinova K, Benoy V, Kutil Z, Zhang G, Tavares MT, Pavlicek J, Zimprich CA, Robers MB, Van den Bosh L, Bařinka C*, Langley B*, Kozikowski A*: Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model. J Med Chem, 2021, 64(8):4810-4840.
(72) Temml V and Kutil Z*: Structure-based molecular modeling in SAR analysis and lead optimization. Comput Struct Biotechnol J, 2021, 19:1431-1444.
(71) Krchlíková V, Mikešová J, Geryk J, Bařinka C, Nexo E, Fedosov SN, Kosla J, Kučerová D, Reinišová M, Hejnar J, Elleder D*: The avian retroviral receptor Tva mediates the uptake of transcobalamin bound vitamin B12 (cobalamin). J Virol, 2021, 95(8):e02136-20.
(70) Jenickova I, Kasparek P, Petrezselyova S, Elias J, Prochazka J, Kopkanova J, Navratil M, Barinka C, Sedlacek R*: Efficient allele conversion in mouse zygotes and primary cells based on electroporation of Cre protein. Methods, 2021, 191:87-94.
(69) Novakova Z*, Belousova N, Foss CA, Havlinova B, Gresova M, Das G, Lisok A, Prada A, Barinkova M, Hubalek M, Pomper MG, Barinka C*: Engineered fragments of the PSMA-specific 5D3 antibody and their functional characterization. Int J Mol Sci, 2020, 21(18):E6672.
(68) Cardinale J, Roscher M, Schäfer M, Geerlings M, Benešová M, Bauder-Wüst U, Remde Y, Eder M, Nováková Z, Motlová L, Barinka C, Giesel FL, Kopka K*: Development of PSMA-1007 – Related Series of 18F-Labeled Glu-ureido type PSMA inhibitors. J Med Chem, 2020, 63(19):10897-10907.
(67) Noonepalle S, Shen S, Ptacek J, Tavares MT, Zhang G, Stransky J, Pavlicek J, Ferreira GM, Hadley M, Pelaez G, Bařinka C*, Kozikowski A*, Villagra A*: Rational Design of Suprastat, a Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. J Med Chem, 2020, 63(18):10246-10262.
(66) Huang C, Guo X, Bařinka C, Lupold SE, Pomper MG, Gabrielson K, Rama V, Artemov D, Hapuarachchige S*: Development of 5D3-DM1: A novel anti-PSMA antibody-drug conjugate for PSMA-positive prostate cancer therapy. Mol Pharmaceut, 2020, 17(9):3392-3402.
(65) Henrichs V, Grycova L, Barinka C, Nahacka Z, Neuzil J, Diez S, Rohlena J, Braun M, and Lánský Z*: Mitochondria-adaptor TRAK1 promotes kinesin-1 driven transport in crowded environments. Nat Commun, 2020, 11(1):3123.
(64) Ptacek J, Zhang D, Liu Q, Kruspe S, Motlova L, Kolenko P, Novakova Z, Shubham S, Havlinova B, Baranova P, Chen SJ, Zou X, Giangrande P, Barinka C*: Structural Basis of Prostate-specific Membrane Antigen Recognition by the A9g RNA Aptamer. Nucl Acid Res, 2020, 48(19):11130-11145.
(63) Kim K, Kwon H, Barinka C, Motlova L, Nam SJ, Choi D, Ha H, Nam H, Son SH, Minn I, Pomper MG, Yang X, Kutil Z*, Byun Y*: Novel β- and γ-amino acid derived inhibitors of prostate-specific membrane antigen. J Med Chem, 2020, 63(6):3261-3273.
(62) Ustinova K, Novakova Z, Saito M, Meleshin M, Mikesova J, Kutil Z, Baranova P, Havlinova B, Schutkowski M, Matthias P, Barinka C*: The disordered N-terminus of HDAC6 is a microtubule-binding domain critical for efficient tubulin deacetylation. J Biol Chem, 2020, 295(9):2614-2628.
(61) Shen S, Svoboda M, Zhang G, Cavasin M, Motlova L, McKinsey T, Eubanks J, Bařinka C, Kozikowski A*: Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor. ACS Med Chem Lett, 2020, 11(5):705-712.
(60) Hapuarachchige S, Huang C, Donnelly M, Bařinka C, Lupold S, Pomper MG, Artemov D*: Cellular delivery of bioorthogonal pretargeting therapeutics in PSMA-positive prostate cancer. Mol Pharmaceut, 2020, 17(1):98-108.
(59) Zessin M, Kutil Z, Meleshin M, Novakova Z, Ghazy E, Kalbas D, Marek M, Romier C, Sippl W, Barinka C, Schutkowski M*: One-Atom-Substitution Enables Direct and Continuous Monitoring of Histone Deacylase Activity. Biochemistry, 2019, 58(48):4777-4789.
(58) Kutil Z, Mikesova J, Zessin M, Meleshin M, Novakova Z, Alquicer GB, Kozikowski A, Sippl W, Barinka C*, Schutkowski M*: A continuous activity assay for HDAC11 enabling re-evaluation of HDAC inhibitors. ACS Omega, 2019, (4)22:19895-19904.
(57) Shen S, Hadley M, Ustinova K, Pavlicek J, Knox T, Noonepalle S, Tavares MT, Zhang G, Zimprich C, Robers M, Bařinka C, Kozikowski AP*, Villagra A*: Discovery of a New Isoxazole-3-hydroxamate Based Histone Deacetylase 6 Inhibitor SS-208 with Anti-tumor Activity in Syngeneic Melanoma Mouse Models. J Med Chem, 2019, 62(18):8557-8577.
(56) Wu H, Yang K, Zhang Z, Leisten ED, Li Z, Xie H, Liu J, Smith KA, Novakova Z, Barinka C, Tang W*: Development of Multi-Functional Histone Deacetylase 6 Degraders with Potent Anti-Myeloma Activity. J Med Chem, 2019, 62(15):7042-7057.
(55) Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A*: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep, 2019, 9(1):6136. 
(54) Kozikowski AP*, Shen S, Pardo M, Tavares MT, Szarics D, Benoy V, Zimprich CA, Kutil Z, Zhang G, Bařinka C, Robers MB, Van Den Bosch L, Eubanks JH, Jope RS: Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS Chem Neurosci, 2019, 10(3):1679-1695.
(53) Banerjee SR, Kumar V, Lisok A, Plyku D, Brummet M, Wharram B, Nováková Z, Barinka C, Hobbs R, Pomper MG: Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. J Nucl Med, 2019, 60(3):400-406.
(52) Barinka C*, Novakova Z, Hin N, Bím D, Ferraris DV, Duvall B, Kabarriti G, Tsukamoto R, Budesinsky M, Motlova L, Rojas C, Slusher BS, Rokob TA, Rulíšek L*, Tsukamoto T*: Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors. Bioorg Med Chem, 2019, 27(2):255-264.
(51) Kutil Z, Skultetyova L, Rauh D, Meleshin M, Snajdr I, Novakova Z, Mikesova J, Pavlicek J, Hadzima M, Baranova P, Havlinova B, Majer P, Schutkowski M*, Barinka C*: The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries. FASEB J, 2019, 33(3):4035-4045.
(50) Porter NJ, Shen S, Barinka C, Kozikowski AP, Christianson DW*: Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor. ACS Med Chem Lett, 2018, 9(12):1301-1305.
(49) Nakajima R$, Novakova Z$, Tueckmantel W, Motlova L, Barinka C*, Kozikowski AP*: 2-Aminoadipic Acid-C(O)-Glutamate Based Prostate-Specific Membrane Antigen Ligands for Potential Use as Theranostics. ACS Med Chem Lett, 2018, 9(11):1099-1104.
(48) Ptacek J, Nedvedova J, Navratil M, Havlinova B, Konvalinka J, Barinka C*: The calcium-binding site of human glutamate carboxypeptidase II is critical for dimerization, thermal stability and enzymatic activity. Prot Sci, 2018, 27(9):1575-1584.
(47) Kutil Z, Novakova Z, Meleshin M, Mikesova J, Schutkowski M, Barinka C*: Histone deacetylase 11 is a fatty-acid deacylase. ACS Chem Biol, 2018, 13(3):685-693.
(46) Skultetyova L, Ustinova K, Kutil Z, Novakova Z, Pavlicek J, Mikesova J, Trapl D, Baranova P, Havlinova B, Hubalek M, Lansky Z, Barinka C*: Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules. Sci Rep, 2017 7(1):11547-515.
(45) Tavares MT, Shen S, Knox T, Hadley M, Kutil Z, Barinka C, Villagra A, Kozikowski AP: Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models. ACS Med Chem Lett, 2017 8(10):1031-1036.
(44) Kopka K, Benešová M, Barinka C, Haberkorn U, Babich J: Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med, 2017 58:17S-26S.
(43) Rais R, Vávra J, Tichý T, Dash RP, Gadiano AJ, Tenora L, Monincova L, Barinka C, Alt J, Zimmermann SC, Slusher CE, Wu Y, Wozniak K, Majer P, Tsukamoto T, Slusher BS: Discovery of a para-acetoxy-benzyl ester prodrug of a hydroxamate-based Glutamate Carboxypeptidase II inhibitor as oral therapy for neuropathic pain. J Med Chem. 2017 60(18):7799-7809.
(42) Lv W, Zhang G, Barinka C, Eubanks JH, Kozikowski AP: Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. ACS Med Chem Lett, 2017 8(5):510-515.
(41) Novakova Z, Foss C, Copeland B, Morath V, Baranova P, Havlinova B, Skerra A, Pomper M, Barinka C*: Novel monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) as research and theranostic tools. The Prostate. 2017, 77(7):749-764.
(40) Conway RE, Rojas C, Alt J, Nováková Z, Richardson SM, Rodrick TC, Fuentes JL, Richardson NH, Attalla J, Stewart S, Fahmy B, Barinka C, Ghosh M, Shapiro LH, Slusher BS: Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis. 2016, 19(4): 487 – 500.
(39) Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, VanBrocklin HF: Structure-Activity Relationship of 18F-labeled phosphoramidate peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-targeted inhibitor analogues for PET imaging of prostate cancer. J Med Chem. 2016, 59(12): 5684 – 5694.
(38) Novakova Z, Wozniak K, Jancarik A, Rais R, Wu Y, Pavlicek J, Ferraris DV, Havlinova B, Ptacek J, Vavra J, Hin N, Rojas C, Majer P, Slusher BS, Tsukamoto T, Barinka C*: Unprecedented binding mode of hydroxamate-based inhibitors of glutamate carboxypeptidase II: structural characterization and biological activity. J Med Chem. 2016, 59(10): 4539 – 4550.
(37) Bumba L, Masin J, Macek P, Wald T, Motlova L, Bibova I, Klimova N, Bednarova L, Veverka V, Kachala M, Svergun DI, Barinka C, Sebo P: Calcium-driven folding of RTX domain β-rolls ratchets translocation of RTX proteins through type I secretion ducts. Mol Cell. 2016, 62(1): 47 – 62.
(36) Barinka C*, Ptacek J, Richter A, Novakova Z, Morath V, Skerra A*: Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA). Protein Eng Des Sel. 2016, 29(3): 105 – 115.
(35) Novakova Z, Cerny J, Choy CJ, Nedrow J, Choi JK, Lubkowski J, Berkman CE, Barinka C*: Design of composite inhibitor targeting glutamate carboxypetidease II: the importance of effector functionalities. FEBS J. 2016, 283(1): 130 – 143.
(34) Youn S, Kim K, Ptacek J, Ok K, Novakova Z, Kim J, Koo J, Barinka C*, Byun Y*: Carborane-containing urea-based inhibitors of glutamate carboxypepitdase II: Synthesis and structural characterization. Bioorg Med Chem Lett. 2015, 25(22): 5232 – 5236.
(33) Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Bařinka C, Jones EF, VanBrocklin HF, Berkman CE: A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015, 42(10): 780- 787.
(32) Tykvart J, Bařinka C, Svoboda M, Navrátil M, Souček R, Hubálek M, Hradílek M, Šácha P, Lubkowski J, Konvalinka J: Structural and biochemical characterization of a novel aminopeptidase from human intestine. J Biol Chem. 2015, 290(18): 11321- 11336.
(31) Tykvart J, Navrátil M, Sedlák F, Corey E, Colombatti M, Fracasso G, Koukolík F, Bařinka C, Šácha P, Konvalinka J: Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate. 2014, 74(16): 1674 – 1690.
(30) Navrátil M, Ptáček J, Šácha P. Starková J, Lubkowski J, Bařinka C, Konvalinka J: Structural and Biochemical Characterization of the Folyl-poly-γ-L-glutamate Hydrolyzing Activity of Human Glutamate Carboxypeptidase II. FEBS J. 2014, 281(14):3228-3242.
(29) Pavlíček J, Ptáček J, Černý J, Byun Y, Škultétyová L, Pomper MG, Lubkowski J, and Bařinka C*: Structural characterization of P1′-diversified urea-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2014, 24(10):2340-2345.
(28) Alquicer G, Sedlák D, Byun Y, Pavlíček J, Stathis M, Rojas C, Slusher B, Pomper MG, Bartůněk P, and Bařinka C*: Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase II. J Biomol Screening 2012, 17:1030-1040.
(27) Tykvart J, Sacha P, Barinka C, Knedlik T, Starkova J, Lubkowski J, Konvalinka J: Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. Protein Expr Purif 2012, 82:106-115.
(26) Pavlicek J, Ptacek J, Barinka C*: Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the Enzyme. Curr Med Chem 2012, 19:1300-1309.
(25) Barinka C*, Rojas C, Slusher B, Pomper M: Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer. Curr Med Chem 2012, 19:856-870.
(24) Plechanovova A, Byun Y, Alquicer G, Skultetyova L, Mlcochova P, Nemcova A, Kim HJ, Navratil M, Mease R, Lubkowski J, Pomper MG, Konvalinka J, Rulisek L, Barinka C*: Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem 2011, 54:7535-7546.
(23) Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL, Lubkowski J, Spiegel DA: A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc 2010, 132:12711-12716.
(22) Zhang Y, Doherty T, Li J, Lu W, Barinka C, Lubkowski J, Hong M: Resonance assignment and three-dimensional structure determination of a human alpha-defensin, HNP-1, by solid-state NMR. J Mol Biol 2010, 397:408-422.
(21) Wang H, Byun Y, Barinka C, Pullambhatla M, Bhang HE, Fox JJ, Lubkowski J, Mease RC, Pomper MG: Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 2010, 20:392-397.
(20) Mlcochova P, Barinka C, Tykvart J, Sacha P, Konvalinka J: Prostate-specific membrane antigen and its truncated form PSM’. Prostate 2009, 69:471-479.
(19) Klusak V#, Barinka C#, Plechanovova A, Mlcochova P, Konvalinka J, Rulisek L, Lubkowski J: Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry 2009, 48:4126-4138.
(18) Hlouchova K, Barinka C, Konvalinka J, Lubkowski J: Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS J 2009, 276:4448-4462.
(17) Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, Barinka C, Konvalinka J: Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 2008, 68:171-182.
(16) Barinka C, Prahl A, Lubkowski J: Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr 2008, 64:273-278.
(15) Barinka C*, Hlouchova K, Rovenska M, Majer P, Dauter M, Hin N, Ko YS, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J.: Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol 2008, 376:1438-1450.
(14) Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J: Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem 2008, 51:7737-7743.
(13) Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J: Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007, 144:1361-1372.
(12) Mlcochova P, Plechanovova A, Barinka C, Mahadevan D, Saldanha JW, Rulisek L, Konvalinka J: Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. FEBS J 2007, 274:4731-4741.
(11) Hlouchova K, Barinka C, Klusak V, Sacha P, Mlcochova P, Majer P, Rulisek L, Konvalinka J: Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 2007, 101:682-696.
(10) Barinka C*, Starkova J, Konvalinka J, Lubkowski J: A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007, 63:150-153.
(9) Barinka C, Rovenska M, Mlcochova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J: Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 2007, 50:3267-3273.
(8) Mesters JR#, Barinka C#, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006, 25:1375-1384.
(7) Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J: Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 2006, 363:482-495.
(6) Caffrey CR, Placha L, Barinka C, Hradilek M, Dostal J, Sajid M, McKerrow JH, Majer P, Konvalinka J, Vondrasek J: Homology modeling and SAR analysis of Schistosoma japonicum cathepsin D (SjCD) with statin inhibitors identify a unique active site steric barrier with potential for the design of specific inhibitors. Biol Chem 2005, 386:339-349.
(5) Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, Konvalinka J: Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004, 13:1627-1635.
(4) Barinka C, Mlcochova P, Sacha P, Hilgert I, Majer P, Slusher BS, Horejsi V, Konvalinka J: Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur J Biochem 2004, 271:2782-2790.
(3) Strisovsky K, Jiraskova J, Barinka C, Majer P, Rojas C, Slusher BS, Konvalinka J: Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate. FEBS Lett 2003, 535:44-48.
(2) Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J: Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002, 80:477-487.
(1) Rinnova M, Hradilek M, Barinka C, Weber J, Soucek M, Vondrasek J, Klimkait T, Konvalinka J: A picomolar inhibitor of resistant strains of human immunodeficiency virus protease identified by a combinatorial approach. Arch Biochem Biophys 2000, 382:22-30.
